^
    Back
    Association details:
    Biomarker:MET mutation
    Cancer:Gastric Cancer
    Drug:elzovantinib (TPX-0022) (Src kinase inhibitor, c-MET inhibitor, CSF-1R inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

    Excerpt:
    ......
    Trial ID:
    SHIELD-1
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Turning Point Therapeutics Press Release
    Title:

    Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium

    Published date:
    10/24/2020
    Excerpt:
    Turning Point Therapeutics...today reported initial clinical data from the ongoing Phase 1 dose finding portion of its SHIELD-1 study of drug candidate, TPX-0022...of 10 MET TKI-naive patients, five achieved a partial response, including three with GC or GEJ cancer, one with CRC, and one with NSCLC. All three evaluable patients with gastric or GEJ tumors achieved a response.